Yes IMO she would be all over the only overwhelming ODAC vote of 9-1 for a treatment for children under 12 that was rejected previously .... I guess we will soon see
I mean they are still making Remestemcel-L according to today's announcement so they must have some confidence in the FDA appeals process or is it for ARDS - 'larger market opportunities' ?
Investment in commercial supply of remestemcel-L ahead of potential approval for graft versus host disease in children and in optimized manufacturing for larger market opportunities.
MSB Trading 2021 - paradigm shift, page-2427
-
- There are more pages in this discussion • 7,784 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.015(1.28%) |
Mkt cap ! $1.353B | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.22 | $1.17 | $4.112M | 3.471M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 29200 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 52347 | 9 |
View Market Depth
| Last trade - 15.03pm 01/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |